Table 1

Patient characteristics

Patient	Age (years)	Sex	Race/ ethnicity	Histology/tumor virus status	CSF disease	# Prior therapies	Antiretroviral therapy	Baseline ECOG	Baseline CD4⁺ T cells/μL	Baseline CD4⁺:CD8⁺ T cell ratio
1	47	M	White	Peritoneal PEL, KSHV⁺/EBV^–	–	2	DOL, TAF, FTC	1	132	0.41
2	53	M	White	MYC rearranged GCB DLBCL, EBV^–	–	4	DOL, TDF, FTC	0	204	0.21
3	43	M	Hispanic	Extracavitary PEL, KSHV⁺/EBV⁺	–	5	Darunavir, ritonivir, DOL, TDF, FTC	1	228	0.39
4	53	M	Black	Aggressive B cell lymphoma, NOS*	–	1	Darunavir, cobicistat, DOL, TAF, FTC	0	557	0.47
5	34	F	White	Non-GCB DLBCL, EBV⁺	–	3	DOL, TAF, FTC	4	43	0.34
6	52	M	Black	Extracavitary PEL†, KSHV⁺/EBV⁺	+	2	DOL, abacavir, 3TC	0	301	0.66
7	35	M	Black	Pleural/pericardial PEL, KSHV⁺/EBV⁺	+	2	DOL, TAF, FTC	3	224	0.81
8	67	F	Black	Non-GCB DLBCL, EBV^–	+	4	BIC, TAF, FTC	1	394	0.23
9	45	F	Hispanic	PBL, EBV⁺	–	1	BIC, TAF, FTC	3	107	0.17
10	36	M	White	Peritoneal PEL, KSHV⁺/EBV⁺	+	2	BIC, TAF, FTC	3	143	0.10

*EBV status of the tumor could not be determined in this patient.
†Patient 6 was treated for leptomeningeal PEL only. The patient’s systemic PEL was in complete remission at treatment initiation.
BIC, bictegravir; CSF, cerebrospinal fluid; DLBCL, diffuse large B cell lymphoma; DOL, dolutegravir; EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group performance score; F, cisgender female; FTC, emtricitabine; GCB, germinal center B cell; KSHV, Kaposi sarcoma herpesvirus; M, cisgender male; NOS, not otherwise specified; PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma; TAF, tenofovir alafenamide fumarate; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.